Thalidomide Survivors Compensation Act of 2025
HB5865, titled the Thalidomide Survivors Compensation Act of 2025, would create a federal compensation program within the Department of Health and Human Services for individuals injured by in utero exposure to thalidomide. The bill’s findings describe thalidomide’s historical role in causing severe birth defects and note that some U.S. survivors still live with lifelong medical and accessibility needs. The stated purpose is to help survivors live with independence and dignity.
Under the bill, eligible individuals would file a petition with HHS and provide documentation from a physician or other health professional showing both exposure to thalidomide and resulting injury. A panel of legal, medical, thalidomide, and survivor experts would review petitions. If approved, the Secretary of HHS would pay a one-time compensation amount of $150,000. The bill also allows for additional compensation later, subject to appropriations and annual review, to address ongoing medical or other needs.
The bill would also protect these payments from being counted as income or assets for means-tested welfare programs and would exclude the compensation from federal gross income under the Internal Revenue Code. It defines a broad list of means-tested programs for this purpose, including Medicaid, Medicare, SNAP, SSI, housing assistance, education aid, veterans benefits, and other federal benefit programs, while also specifying special rules for refundable tax credits and certain state and local expenditures. The bill authorizes appropriations for fiscal years 2028 through 2034 and requires annual HHS reports to Congress on program performance, spending, recipient numbers, and survivor feedback.
The bill’s impact on state and federal law would be primarily at the federal level, by creating a new compensation entitlement-like program and amending the tax code. It would not directly change state statutes, but it could affect how state-administered benefit programs interact with federal compensation by excluding these payments from means-tested eligibility calculations. It also establishes a new administrative review and reporting structure within HHS and creates a new tax exclusion for recipients.
Overall sentiment appears supportive and remedial, with the bill framed as a long-overdue effort to recognize and compensate a small population of aging survivors for decades of harm and unreimbursed costs. No committee debate or recorded votes were provided, so there is no evidence of formal opposition in the available materials. The main potential points of contention are likely to be eligibility limits, including the requirement that petitioners be U.S. citizens or permanent residents at the time of exposure and submission, the need to prove exposure and injury, the fixed $150,000 payment amount, and the breadth of the bill’s definition of means-tested welfare programs for income-exclusion purposes.
The bill would create a new federal compensation program administered by HHS, establish petition and review procedures, authorize appropriations for FY 2028-2034, and amend the Internal Revenue Code to exclude thalidomide compensation from gross income. It would also direct that these payments not count as income or assets for a wide range of means-tested federal benefit programs, potentially affecting eligibility determinations for recipients across public assistance, health care, housing, nutrition, education, and veterans-related programs.
The available text presents the bill in strongly sympathetic terms, emphasizing historical injustice, survivor hardship, and the goal of restoring dignity and independence. Because there are no committee transcripts or votes, the record does not show organized opposition or amendment activity. On its face, the measure appears to be framed as a targeted compensation and recognition bill with generally favorable policy intent.
No formal contention is documented in the provided materials, but the bill contains several provisions that could draw scrutiny. Eligibility is limited to American citizens or permanent residents, and petitioners must prove both exposure and injury, which may be difficult given the passage of time. The $150,000 payment amount and the open-ended possibility of additional compensation depend on appropriations and HHS discretion, which could raise concerns about adequacy and administrative burden. The bill’s expansive definition of means-tested welfare programs, including programs such as Medicare and Social Security for specified purposes, may also prompt debate over how the compensation interacts with existing benefit systems.